- Trial phase
- Preclinical
- Time to market
- Unknown, preclinical stage; best-case scenario Phase 1 data in 2027, then Phase 2/3 would take several more years. Realistically 5+ years from now if successful.
- Why 4/10
- MT-002 is preclinical with no human data yet. The next hard catalyst is a first-in-human (FIH) regulatory filing expected Q1 2027. Since MT-002 is the secondary asset (behind MT-001) at a company undergoing a reverse merger, and the FIH filing is a non-binary regulatory submission rather than a pivotal readout, the impact on INM stock from MT-002 alone is limited near-term. The merger closing (target Dec 31, 2026) and MT-001's FIH filing (mid-2026) are more impactful near-term events.
MT-002 is very early-stage and won't generate human data until at least late 2027. The nearer-term story for INM is the reverse merger with Mentari Therapeutics closing (target Q4 2026), the $290M PIPE funding, and MT-001's FIH filing. Existing INM shareholders face extreme dilution (~1.51% of the combined entity). This is a pre-revenue, preclinical-stage binary with a long timeline, not a trading catalyst in its own right.
Price Chart
Executive Summary
MT-002 is a preclinical bispecific antibody targeting both CGRP and PACAP pathways for migraine prevention. It is the second pipeline asset (after MT-001) of Mentari Therapeutics, which is merging with micro-cap InMed Pharmaceuticals (INM) in a reverse merger backed by $290M in PIPE financing. MT-002 is potentially first-in-class as a dual-pathway inhibitor but is years away from human proof-of-concept, FIH filings aren't expected until Q1 2027, with Phase 1 data in 2027 at the earliest. The migraine prevention market is large (~$6.5-12B) but intensely competitive, with multiple approved anti-CGRP antibodies (Aimovig, Emgality, Ajovy, Vyepti) and Lundbeck's anti-PACAP antibody bocunebart already in Phase 2b with positive data. Existing INM shareholders are being diluted to ~1.51% of the combined entity, making this effectively a new company listing via reverse merger.
How It Works
MT-002 is a bispecific antibody, a single engineered protein designed to block two different biological targets at once. It targets both CGRP (calcitonin gene-related peptide) and PACAP (pituitary adenylate cyclase-activating polypeptide), two neuropeptides that are known to trigger migraine attacks. By blocking both pathways simultaneously, it aims to provide better migraine prevention than existing drugs that only block one of these targets. About two-thirds of migraine patients don't get adequate relief from current anti-CGRP-only drugs, so the dual mechanism is designed to help that population.
Trial Status
MT-002 is still in preclinical development. First-in-human (FIH) regulatory filings are expected in Q1 2027, with Phase 1 healthy volunteer data expected later in 2027. No clinical trials have been initiated yet. The drug was originally discovered by Paragon Therapeutics and is being developed by Mentari Therapeutics, which is merging into InMed Pharmaceuticals.
The Two-Sided Case
Upcoming Catalysts
- Q3-Q4 2026: MT-001 (anti-PACAP mAb) first-in-human regulatory filing
- Q4 2026: Expected closing of InMed-Mentari reverse merger (target Dec 31, 2026)
- Q1 2027: MT-002 first-in-human regulatory filing expected
- 2027: MT-002 Phase 1 healthy volunteer data expected
- 2028: MT-001 Phase 2a proof-of-concept data expected
Source Filing
The SecBot filing or press-release report that triggered this drug report:
InMed Pharmaceuticals Inc. S-4 INM ·Originating report